Factset Research Systems Inc

FDS is in a Stage 2 advancing regime with clear higher highs and higher lows supported by rising intermediate EMAs, underpinning a bullish medium-term bias. However, price is extended and overbought near the 200 DMA, indicating near-term exhaustion risk. Under the High Quality Dislocated Assets strategy, patient entry should wait for shallow pullbacks into the rising 9 and 21 EMA zone to ensure structural support remains intact.

• ↑Organic ASV up 6.7% YoY to $2.45B, reflecting strong client retention
• ↑Revenue rose 7.1% YoY to $611M; adjusted EPS climbed 4% to $4.46
• ↓Adjusted operating margin fell to 35% amid 9% YoY rise in operating costs